𝔖 Bobbio Scriptorium
✦   LIBER   ✦

CpG Island Hypermethylation Profile in the Serum of Men With Clinically Localized and Hormone Refractory Metastatic Prostate Cancer

✍ Scribed by Bastian, Patrick J.; Palapattu, Ganesh S.; Yegnasubramanian, Srinivasan; Rogers, Craig G.; Lin, Xiaohui; Mangold, Leslie A.; Trock, Bruce; Eisenberger, Mario A.; Partin, Alan W.; Nelson, William G.

Book ID
121889209
Publisher
Lippincott Williams and Wilkins
Year
2008
Tongue
English
Weight
121 KB
Volume
179
Category
Article
ISSN
0022-5347

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

A phase 2 study of carboplatin plus doce
A phase 2 study of carboplatin plus docetaxel in men with metastatic hormone-refractory prostate cancer who are refractory to docetaxel
✍ Robert W. Ross; Tomasz M. Beer; Susanna Jacobus; Glenn J. Bubley; Mary-Ellen Tap 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 79 KB 👁 2 views

## Abstract ## BACKGROUND. Prostate cancer is the second leading cause of cancer mortality among men in the U.S. To the authors' knowledge, there is no proven, effective, second‐line therapy for docetaxel‐refractory disease. Recent data suggest that platinum salts may be effective when combined wi

A phase 3 randomized controlled trial of
A phase 3 randomized controlled trial of the efficacy and safety of atrasentan in men with metastatic hormone-refractory prostate cancer
✍ Michael A. Carducci; Fred Saad; Per-Anders Abrahamsson; David P. Dearnaley; Clau 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 142 KB 👁 2 views

## Abstract ## BACKGROUND. The objective of this study was to evaluate the efficacy and safety of atrasentan (Xinlay), a selective endothelin‐A receptor antagonist, in patients with metastatic hormone‐refractory prostate cancer (HRPC). ## METHODS. This multinational, double‐blind, placebo‐contro